Aspen Neuroscience, a clinical‑stage biotechnology company focused on personalized regenerative therapies, announced that it has completed dosing of the third cohort in its Phase 1/2a ASPIRO trial of ANPD001, an autologous dopaminergic neuronal precursor cell therapy for moderate to advanced Parkinson’s disease. According to the company, cohort three was conducted using a commercial‑ready formulation designed to support scale‑up and reproducible manufacturing, featuring a cryopreserved “thaw‑and‑inject” product that simplifies delivery to clinical sites and reduces demands on hospital cell processing labs. The completion of this cohort marks a meaningful operational milestone as Aspen transitions toward later‑stage development while maintaining the personalized nature of its approach.
In parallel, Aspen announced the completion of its expanded good manufacturing practice (GMP) facility in San Diego, bringing total capacity to nearly 22,000 square feet with state‑of‑the‑art cleanroom suites and automated environmental controls. The facility build‑out is intended to support high‑quality cell therapy production for clinical programmes and future commercial readiness, with the new cleanrooms serving as a template for automated manufacturing scale‑out. According to the company, this infrastructure will enable increased capacity and process control as it progresses toward pivotal studies.
Earlier cohorts in the ASPIRO trial have reported six‑month safety and tolerability data along with clinician‑ and patient‑reported improvements without need for immunosuppression, consistent with Aspen’s autologous strategy. ANPD001 has received Fast Track designation from the U.S. Food and Drug Administration, reflecting regulators’ recognition of the unmet medical need in Parkinson’s disease and the potential of the cell therapy approach. The ASPIRO study continues to follow participants for primary and long‑term endpoints, while the company prepares for subsequent phases of development.
